114 results about "Recombinant antigen" patented technology

The invention provides a joint detection test strip for dengue virus and Zika virus antigens and antibodies and a preparation method of the joint detection test strip. According to the combined detection test strip, the combined detection test strip with the dengue virus NS1 antigen and the dengue virus IgG / IgM antibody adopts a multi-site recombinant antigen labeling or multi-site recombinant antibody coating form, so that the sensitivity of a reagent is improved; the problems of poor specificity and release residue of latex microspheres are solved by optimizing the confining liquid; colored latex microspheres are used as a marker, a detection target is more intuitively distinguished according to line colors, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is more quickly improved, and the dengue virus NS1, the Zika virus NS1 antigen, the dengue virus IgG / IgM antibody and the Zika virus IgG / IgM antibody can be detected at the same time; and the kit is convenient to carry, simple to operate, convenient for on-site instant detection and capable of performing large-scale preliminary screening.

This invention discloses an ANXA1 recombinant antigen, its preparation method, and its applications, belonging to the field of biodetection technology. The ANXA1 recombinant antigen of this invention is based on the wild-type ANXA1 protein shown in SEQ ID NO.1, obtained by deleting its first epitope-masking region, thus making the epitope more easily exposed. Verification has shown that, compared to the full-length ANXA1 antigen, the ANXA1 recombinant antigen of this invention has improved sensitivity in early lung cancer detection, and its detection performance is significantly superior to commercially available ANXA1 recombinant antigens. Therefore, the ANXA1 recombinant antigen of this invention provides a new approach for the early auxiliary diagnosis of lung cancer.

The application provides a kit for detecting neutralizing antibodies of a novel coronavirus, comprising an immunochromatography test paper, the immunochromatography test paper comprising a backing plate and a sample pad, a conjugate pad, a detection pad and a water absorption pad arranged on the backing plate in sequence; the detection pad is provided with a detection line and a quality control line; the sample pad is coated with a recombinant antigen, the recombinant antigen being a fusion protein SARS-CoV-2S-RBD-Fc formed by fusing SARS-CoV-2S-RBD with the Fc fragment of IgG antibody; the conjugate pad is coated with SARS-CoV-2ACE2 labeled with nanoparticles; and the detection line is coated with a polyantibody of anti-IgG antibody. The kit for detecting the application utilizes the principle of competition and sandwich detection, can quickly and simply realize effective detection of neutralizing antibodies of the novel coronavirus, has low cost, high sensitivity and high specificity, and has a good popularization and application prospect.

The present application relates to the technical field of molecular biology, and particularly relates to a human parainfluenza virus type I HN recombinant antigen and application thereof. The amino acid sequence of the human parainfluenza virus type I recombinant HN recombinant antigen provided by the present application is shown as SEQ ID NO:1. The amino acid sequence provided by the present application can be efficiently expressed in insect cells, and a stable antigen can be obtained after purification and preparation of the expression product, and the antigen has high immunological activity and can be used for serum specific antibody detection or parainfluenza virus infection diagnosis.

The invention discloses a recombinant antigen protein, a recombinant vector, a recombinant host cell, a virus-like particle and application thereof and a vaccine, and relates to the technical field of antigen preparation, the recombinant antigen protein comprises an icosahedral porcine circovirus capsid protein and an A104R protein loaded on the surface of the icosahedral porcine circovirus capsid protein, the A104R protein comprises a protein coded by an African swine fever virus A104R gene. The recombinant antigen protein capable of simultaneously reacting with positive serum of the African swine fever virus and positive serum of the porcine circovirus is prepared, and the vaccine prepared by mixing the recombinant antigen protein with an adjuvant can effectively stimulate a pig body to generate specific antibodies of the African swine fever virus and the porcine circovirus; therefore, reference is provided for joint defense of the two viruses. The recombinant antigen protein provided by the invention has the characteristics of stable expression, high yield and high solubility.

This invention provides a recombinant conjugate protein against EBV virus and its application. The recombinant conjugate protein is a conjugate of recombinant protein HBc-SC and recombinant EBV antigen protein. In the recombinant conjugate protein, the molar ratio of recombinant protein HBc-SC to recombinant EBV antigen protein is 1:1 to 1:12. The amino acid sequence of the recombinant protein HBc-SC is shown in SEQ ID NO:1. The recombinant EBV antigen protein includes a recombinant gHgL fragment and a tag sequence. The recombinant gHgL fragment is shown in SEQ ID NO:3. The tag sequence is shown in SEQ ID NO:5, and the tag sequence is located at the C-terminus of the recombinant EBV antigen protein. The recombinant conjugate protein provided by this invention can induce strong humoral immunity, significantly increasing neutralizing antibody titers in epithelial cells and B cells, making it an excellent candidate vaccine for preventing EBV virus infection.

The application provides a recombinant antigen protein p22 of an African swine fever virus, a monoclonal antibody and application. The application provides a recombinant antigen protein of an African swine fever virus. The application provides an antibody or antigen binding fragment thereof of the recombinant antigen protein of the African swine fever virus. The application also provides a hybridoma cell. The application also provides a rapid detection test paper card of the African swine fever antibody. The recombinant antigen protein of the African swine fever virus provided by the application has higher affinity to the African swine fever antibody, higher specificity and better stability, and can be used for rapid and accurate detection of the African swine fever virus.

The invention discloses a MAGE A1 recombinant antigen as well as a preparation method and application thereof, and belongs to the technical field of biological detection. The amino acid sequence of the MAGE A1 recombinant antigen disclosed by the invention is as shown in SEQ ID NO. 1. Through verification, compared with a full-length MAGE A1 antigen, the MAGE A1 recombinant antigen disclosed by the invention has the advantage that the sensitivity of the MAGE A1 recombinant antigen in early lung cancer detection is improved. Therefore, the MAGE A1 recombinant antigen provides a new way for early auxiliary diagnosis of lung cancer.

The present invention relates to a lymphocyte comprising a recombinant nucleic acid encoding a fusion protein comprising interleukin-15 (IL-15) fused to interleukin-21 (IL-21), and optionally further comprising a recombinant antigen receptor and further optionally rendered independent of CD28 co-stimulation and resistant to exhaustion as caused by checkpoint protein expression and activation. The invention further encompasses the use of such lymphocytes, particularly in therapeutic applications such as adoptive cell therapy for cancer, autoimmune diseases, or infectious diseases. Also included within the scope of the invention are fusion proteins comprising IL-15 and IL-21 domains, nucleic acids encoding such fusion proteins, and cells—such as lymphocytes or other suitable host cells—comprising these nucleic acids.

The present application relates to the technical field of antibodies, in particular to preparation and application of anti-influenza B virus monoclonal antibody, and provides the antibody and application thereof, nucleic acid molecule, expression vector, genetic engineering biological material, quality control product and preparation method, reagent and kit thereof.The anti-FluB monoclonal antibody can be used as quality control product and calibration product, can significantly cause enzyme-linked immuno reaction with Victoria and Yamagata system recombinant antigens of FluB virus HA gene, and the 37 DEG C acceleration stability experiment result shows that it meets the kit use requirement, the preparation method is simple, and is suitable for mass production.

This invention relates to an ELISA detection kit for porcine reproductive and respiratory syndrome virus (PRRSV) based on M-GP5 recombinant protein, and belongs to the field of ELISA detection technology. The kit includes recombinant (M-GP5) antigen protein, an ELISA plate, blocking buffer, primary antibody dilution buffer, enzyme-labeled secondary antibody, secondary antibody dilution buffer, chromogenic solution, stop solution, negative serum, and positive serum. It features high sensitivity, high specificity, and good stability, and can accurately detect PRSV antibodies.

The invention discloses a hybridoma cell strain secreting a CFP10 antibody, the antibody and application of the hybridoma cell strain in magnetic particle chemiluminescence detection, the hybridoma cell strain is 2E7 and is preserved in the China Center for Type Culture Collection on May 14, 2025, and the preservation number is CCTCC NO: C2025162. The monoclonal antibody 2E7 provided by the invention has the advantages of high titer, good specificity and strong affinity with natural antigens and recombinant antigens, and can specifically recognize recombinant antigens rHis-CFP10 and rGST-CFP10 and a CFP10 antigen in a natural antigen H37Ra strain. The magnetic particle chemiluminescence detection method established by the invention is simple to operate, low in cost and wider in applicability.

The application discloses a recombinant FCV antigen and a construction method and application thereof. The construction method of the recombinant FCV antigen comprises the following steps: fusing a T cell epitope coding sequence of a non-structural protein NS7 of FCV and a coding sequence of a SpyTag peptide segment through a coding sequence of a linker, then cloning into a baculovirus transfer vector to obtain a recombinant plasmid, and finally integrating the T cell epitope coding sequence into Bacmid through Tn7 transposition to finally obtain the recombinant FCV antigen. The application selects NS7 as a core immunogen, guides the immune system to produce a high cellular immune response, and thus makes up for the deficiency of an existing vaccine in clearing intracellular viruses; meanwhile, a specific T cell epitope is selected in the sequence of NS7 as an immunogen, which can avoid the immunological escape caused by the variation degree of antigens among different strains and virus antigen drift, and thus provides broader protection.

The invention discloses a neutralizing antibody with an AQP3 channel blocking function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The neutralizing antibody can be specifically combined with an extracellular domain of AQP3, after combination, a water channel and a small molecule transport function of the AQP3 are blocked through steric hindrance and conformation change, and meanwhile, antigen combination specificity is reserved. The preparation method is realized through'recombinant antigen-immunization-B cell screening culture-recombinant antibody expression and affinity purification-ELISA detection ', and the functions of the antibody are ensured. The antibody can be efficiently combined with AQP3 positive cells, is strong in targeting property and high in specificity (the serum titer reaches 1: 1024 * 10, and the purified antibody titer is greater than or equal to 1: 128 * 10), and can be independently used or combined with a nano-carrier for treating related diseases, so that the technical bottleneck that a common AQP3 antibody can only be combined and cannot efficiently play a blocking role is solved.

The application provides a combined detection test strip for dengue virus, Zika virus antigen and antibody and a preparation method thereof; the combined detection test strip of the application adopts a multi-site recombinant antigen marking or multi-site recombinant antibody coating form for the combined detection test strip for dengue virus NS1 antigen and dengue virus IgG / IgM antibody, thereby improving the sensitivity of the reagent; the application also overcomes the problems of poor specificity and release residue of the latex microspheres by optimizing a blocking solution; color latex microspheres are used as the markers, the target is more intuitively detected according to the color of the lines, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is improved, dengue virus NS1, Zika virus NS1 antigen, dengue virus IgG / IgM antibody detection and Zika virus IgG / IgM antibody can be simultaneously detected; moreover, the application is convenient to carry and easy to operate, is convenient for on-site instant detection and can be used for large-scale preliminary screening.

The present invention relates to a test kit for performing an assay to detect and measure at least one autoantibody molecule in a subject developing type 1 diabetes (T1D). The invention more specifically relates to a recombinant antigen molecule fused to a bioluminescent reporter protein to detect an autoantibody molecule against a self-antigen. Said self-antigen is preferably expressed by pancreatic islet beta cells and include insulin, proinsulin, Glutamate decarboxylase 65, islet antigen 2, and Zinc transporter 8. More specifically, the present invention relates to an assay comprising a set of at least three recombinant antigen molecules in a single composition, the antigen molecules being selected from the list comprising recombinant human Glutamate decarboxylase 65, recombinant human islet antigen 2, recombinant human Zinc transporter 8, recombinant human insulin, and recombinant human proinsulin. The invention further relates to methods for determining the presence and / or level of at least one autoantibody molecule in a sample from a human subject developing T1D using said recombinant antigen molecules. According to the invention, the presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.

The application discloses a kind of modular serum-free cell culture medium and its application, belong to biomedical technology field.The culture medium includes: epidermal growth factor, recombinant insulin, cholesterol-phospholipid nanoparticles, beta-mercaptoethanol, pluronic F-68, glucose / glutamine, trace element mixed solution.The modular serum-free cell culture medium provided by the application can not only meet the large-scale culture of stem cells, but also be used for the industrial production of in vitro diagnostic reagent raw materials such as recombinant antigen, viral vector, recombinant protein and monoclonal antibody, with wide cell adaptability, low production cost, significant economy, stable process, and strict requirements of FDA / EMA for biological products.

The invention discloses a latex microsphere identification and detection test strip for detecting a bovine leukemia virus antibody and application thereof. The test strip comprises a chromatography membrane, a water absorption pad, a latex labeling pad and a sample pad which are adhered to a PVC (polyvinyl chloride) bottom plate, a quality control line and a detection line are arranged on the chromatography membrane; the detection line is formed by spraying a BLV gp51 recombinant antigen protein, and the quality control line is formed by spraying a goat anti-chicken IgY antibody; the latex labeling pad is sprayed with BLV gp51 recombinant antigen protein and a chicken IgY antibody which are combined with the red latex microspheres. According to the invention, the BLV gp51 prokaryotic expression antigen and the red latex microsphere immunochromatography technology are combined for the first time, a double-antigen sandwich detection system suitable for the field is established, the dependence of traditional ELISA on equipment and operation environment is broken through, and the high specificity (gt; according to the present invention, the rapid interpretation within 15 min is achieved while the detection limit is 1: 256, such that the reliable and convenient technical tool is provided for the basic level prevention and control of the BLV.

This invention discloses a multi-epitope virus-like particle antigen (VLP) of type O foot-and-mouth disease virus (FMDV), its preparation method, and its application. The type O FMDV VLP antigen is a recombinant antigen protein formed by sequentially tandemly connecting the antigenic epitopes of five representative strains of type O FMDV topotypes—O / Tibet / CHA / 99, O / Mya98 / BY / 2010, O / HN / CHA / 93, O / XJPS / CHA / 2017, and Cathay—with the SpyCather and bacteriophage AP205 genes, and then tandemly connecting them with the epitopes of the first four strains. This recombinant protein can self-assemble into a VLP antigen. Immunological experiments show that this VLP antigen has good antigenicity, and its antigenic reactivity with type O FMDV is not significantly different, making it a viable alternative to inactivated FMDV antigens in detection methods. Vaccines prepared using this VLP antigen not only induce high levels of protective antibodies but also protect immunized animals against viral challenge. Furthermore, it is not limited by animal species and provides immune protection against type O foot-and-mouth disease in pigs, cattle, and sheep.

The invention discloses a GAGE7 recombinant antigen as well as a preparation method and application thereof, and belongs to the technical field of biological detection. The amino acid sequence of the GAGE7 recombinant antigen is shown as SEQ ID NO.1. Through verification, compared with a wild type GAGE7 antigen, the detection sensitivity of the GAGE7 recombinant antigen is remarkably improved, and meanwhile, the performance of the GAGE7 recombinant antigen is obviously superior to that of a commercially available GAGE7 recombinant antigen. Therefore, the GAGE7 recombinant antigen has a good application prospect in the field of early detection of lung cancer.

The present invention relates to a novel recombinant antigen protein for Japanese encephalitis and, more specifically, to a recombinant antigen protein for Japanese encephalitis, designed through protein structural stability analysis and introduction of point mutations. It has been identified that a composition comprising the recombinant antigen protein for Japanese encephalitis, according to the present invention, exhibits immunogenicity and protective efficacy against challenge inoculation that are superior to those of an approved live-attenuated vaccine. In particular, it has been experimentally identified that the recombinant antigen protein for Japanese encephalitis, of the present invention, exhibits excellent protective efficacy against Japanese encephalitis virus G5 and other genotypes. Therefore, the recombinant antigen protein for Japanese encephalitis, of the present invention, can be variously used in the field of preventing infection by Japanese encephalitis virus G1 to G5.

The application belongs to the technical field of livestock pathogenic bacteria diagnosis, and particularly relates to a blocking ELISA kit and method for detecting Lawsonia intracellularis antibody. The kit comprises an LI-OmpA recombinant antigen peptide coated ELISA plate, an enzyme-labeled antibody, a positive control, a negative control, a sample diluent, a 20-fold concentrated washing solution, a substrate color developing solution and a termination solution. The method comprises using the LI-OmpA recombinant antigen peptide as a coating antigen and the enzyme-labeled LI-OmpA recombinant antigen peptide monoclonal antibody 5F2 as an enzyme-labeled antibody to establish the blocking ELISA method for the Lawsonia intracellularis antibody. The blocking ELISA kit for the Lawsonia intracellularis antibody provided by the application has the characteristics of high sensitivity and specificity, good repeatability and the like, and is suitable for the detection of high-throughput animal serum samples.

The present invention relates to an RNA molecule encoding a Nipah / Hendea virus recombinant antigen, a vaccine or an immunogenic composition comprising the same, and an application thereof in the preparation of a vaccine for preventing and / or treating Nipah virus and / or Hendea virus infection. The RNA vaccine for coding the Nipa / Hendea virus recombinant antigen can stimulate strong immune response aiming at HeV and NiV at the same time, and has huge value and wide development prospect in the field of clinical application.

The invention belongs to the technical field of biological detection, and particularly relates to an immunodetection reagent for blood virus screening and a preparation method of the immunodetection reagent. The immunodetection reagent comprises the following raw materials in parts by weight: 100 parts of a capture reagent, 300 parts of a sealing agent, 300 parts of a cracking agent, 1 part of an HCV recombinant antigen, 1 part of an anti-HCVcAg monoclonal antibody, 0.2-0.6 part of hydroxymethylcoumarin, 10 parts of BSA, 2-6 parts of glutaric anhydride, 4-8 parts of TEOS and 100 parts of a PBS buffer solution. According to the present invention, the silica microsphere with the HCV recombinant antigen and the anti-HCVcAg monoclonal antibody coupled on the surface and the hydroxymethylcoumarin signal molecule loaded inside is constructed, and the HCV antigen and the HCV antibody in the serum are specifically recognized so as to achieve the efficient diagnosis and detection of the HCV infection in the whole cycle;

This invention discloses a kit for the quantitative detection of C-reactive protein (CRP) in giant pandas and its application, belonging to the field of biodetection technology. The kit disclosed in this invention comprises reagent R2 with the following concentrations: 50 mM PBS pH 7.5, Tween-20 6 ml / L, 270 nm polystyrene carboxylated latex 2.5 g / L, sucrose 30 g / L, BSA 10 g / L, rabbit anti-giant panda CRP polyclonal antibody 6.75 mg / L, and preservative 0.5 ml / L. The rabbit anti-giant panda CRP polyclonal antibody is obtained by immunizing giant white rabbits with the recombinant antigen expressed by the sequence shown in SEQ ID NO. 4. This invention provides a highly efficient, simple, low-cost, and scalable detection method.

The invention discloses a kit for quantitatively detecting panda C-reactive protein and application of the kit, and belongs to the technical field of biological detection. The invention discloses a kit for quantitatively detecting panda C reactive protein. A reagent R2 is prepared from the following components in concentration: 50 mM PBS (Phosphate Buffer Solution) with pH (Potential of Hydrogen) of 7.5, 6 ml / L of tween-20, 2.5 g / L of 270 nm polystyrene carboxyl latex, 30 g / L of sucrose, 10 g / L of BSA (Bovine Serum Albumin), 6.75 mg / L of rabbit anti-panda CRP (C reactive protein) polyclonal antibody and 0.5 ml / L of preservative; the rabbit anti-panda CRP polyclonal antibody is obtained by immunizing a rabbit with a recombinant antigen expressed by the sequence as shown in SEQ ID NO.4. The invention provides a detection scheme which is efficient, simple, convenient, low in cost and capable of being popularized on a large scale.

The invention relates to the technical field of porcine ileitis detection, and particularly discloses a porcine ileitis antibody detection kit, the kit comprises a colloidal gold immunochromatography test strip, a sample treatment liquid and a negative / positive control, a detection line T line of the test strip is coated with a recombinant Lawsonia intracellularis LsaA protein antigen, a quality control line C line is coated with a goat anti-Protein A antibody, and the detection line C line is coated with a goat anti-Protein A antibody. And the colloidal gold labeling pad is coupled with a Protein A-colloidal gold compound. According to the present invention, the prokaryotically expressed recombinant LsaA antigen is adopted to improve the specificity, the ProteinA is adopted to replace the traditional secondary antibody to simplify the labeling process, the sample treatment liquid formula is optimized to reduce the non-specific reaction, and the HOOK effect is inhibited by adjusting the antigen coating concentration and the marker consumption. Rapid detection of the porcine ileitis antibody is realized, sensitivity and specificity are greatly improved, operation is simple and convenient, professional equipment is not needed, and the problems that an existing detection method is time-consuming, low in sensitivity and high in cost are solved.

The invention discloses an HMGCR antigen gene, an HMGCR recombinant antigen gene, a recombinant antigen, a reagent for detecting an anti-HMGCR antibody as well as a preparation method, a detection method and application of the reagent, the HMGCR antigen gene is obtained by modifying a gene for coding HMGCR protein by adopting a codon optimization technology, and the HMGCR recombinant antigen gene is obtained by modifying the optimized HMGCR antigen gene. The nucleotide sequence of HMGCR is optimized by using a codon optimization tool, and the sequence after ATG is subjected to recombination transformation, so that the expression quantity of HMGCR protein is improved; through further recombination transformation, the expression quantity of the HMGCR antigen is further improved, and the expression level of protein can be greatly improved by applying the sequence which is easier to express. The kit can be used for detecting the anti-HMGCR antibody in human body fluid, the detection specificity and sensitivity are improved, and compared with WB, the kit has higher sensitivity and specificity, and the specificity and sensitivity reach 100%.

This invention relates to the field of immunodiagnostics and provides recombinant HIV antigens for HIV antibody detection. Specifically, it concerns recombinant HIV antigens, nucleic acid molecules, expression vectors, host cells, reagents, kits, and their use. When recombinant HIV antigen proteins are used as the labeling end, the marker activity of the recombinant HIV antigen can be significantly improved, and nonspecific immunobinding activity can be reduced, thereby increasing sensitivity.

The present invention discloses a nanobody targeting human epididymal protein 4 (HE4) and its application, relating to the field of bioengineering nanotechnology. The invention prepares a specific nanobody library targeting HE4 by immunizing camels with HE4 recombinant antigens. Phage display technology is then used to screen for HE4-specific nanobodies with high affinity. These nanobodies are highly water-soluble, conformationally stable, and can be successfully induced for expression.